<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, Jaehyuk</style></author><author><style face="normal" font="default" size="100%">Kim, Jinyoung</style></author><author><style face="normal" font="default" size="100%">Jeong, Seongju</style></author><author><style face="normal" font="default" size="100%">Kim, Yuyon</style></author><author><style face="normal" font="default" size="100%">Park, Sang Hyun</style></author><author><style face="normal" font="default" size="100%">Bae, Sungmin</style></author><author><style face="normal" font="default" size="100%">Kim, Daejin</style></author><author><style face="normal" font="default" size="100%">Choi, In Young</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">1046 A long-acting and Beta-intensified IL-2 analog, HM16390, significantly alters tumors to an immune favorable environment to potentiate PD-1 blockade</style></title><secondary-title><style face="normal" font="default" size="100%">Journal for ImmunoTherapy of Cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">A1153-A1153</style></pages><doi><style  face="normal" font="default" size="100%">10.1136/jitc-2023-SITC2023.1046</style></doi><volume><style face="normal" font="default" size="100%">11</style></volume><issue><style face="normal" font="default" size="100%">Suppl 1</style></issue><abstract><style  face="normal" font="default" size="100%">Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.</style></abstract></record></records></xml>